Company intelligence / Profile preview

RemovAid

Ownership: Private
Development stage: Other

Overview

The RemovAid™ device has CE approval as a class IIa medical device for gentle, needle-free removal of single rod contraceptive implants. It has been piloted successfully in Norway with high user satisfaction and plans for broader international distribution[1][2][3]. Clinical results indicate that 97% of women who had their implant removed using RemovAid™ would recommend it to a friend[1].

Therapeutic areas: Women's HealthOther
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Sex og samfunn clinic in Norway ("Sex og samfunn" was first to offer the product through ACCESS Norway project)

Beyond the preview

Go deeper on RemovAid.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RemovAid.

Explore the full profile